key: cord-0974627-uf73vrkp
authors: Somaili, Mohammed; Abu-aishah, Hanadi; Haidar, Wejdan; Hamzi, Shroog; Khubrany, Saad
title: Kidney Transplant Recipient with Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) secondary to COVID-19 pneumonia: A Case Report
date: 2022-04-11
journal: Transplant Proc
DOI: 10.1016/j.transproceed.2022.04.001
sha: 746b9b7e8e49bc9d7437112bc7cacb8735ad18e0
doc_id: 974627
cord_uid: uf73vrkp

Introduction Currently, Coronavirus Disease Infectious Disease -19 (COVID-19) is becoming one of the most common causes of viral pneumonia worldwide. In the medical literature, very few case reports described the association between COVID-19 and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in kidney transplant patients. Patient concern a 74-year-old immunocompromised man who is a post kidney transplant, presented with non-specific symptoms consisting of fatigue, malaise, and anorexia. He also found to have hyponatremia in the context of pulmonary insults. Diagnosis Syndrome of inappropriate antidiuretic hormone secretion in setting of COVID-19 pneumonia was diagnosed after exclusion of other causes of hyponatremia. Intervention Treatment of COVID-19 pneumonia with antiviral therapy, secondary bacterial infection prophylaxis, dexamethasone and ventilatory support in addition to modification of anti-rejection medications. Outcome The patient has improved and his serum sodium normalized with management of primary insult. Conclusion SIADH should be suspected in transplant patient with COVID-19 pneumonia once he develops hyponatremia. The decision of intravenous fluid administration should be taken carefully in these settings.

The current coronavirus disease pandemic, caused by the severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) is a serious public health concern worldwide (1).

The clinical presentation of COVID-19 ranges from mild disease with upper respiratory tract symptoms to a severe form of the disease with pneumonia and organ failure. Pulmonary manifestations of COVID-19 include fever, fatigue, shortness of breath, and cough (2).

The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is characterized by impaired water excretion secondary to the inability to inhibit antidiuretic hormone (ADH) secretion (3) . SIADH, characterized by uncontrolled release of ADH, occurs when the total body water content exceeds urinary excretion, commonly referred to as euvolemic dilutional hyponatremia (3, 4) .

The mechanism underlying hyponatremia in patients with COVID-19 is excessive release of inflammatory cytokines, including interleukin (IL)-1β, IL-6, and the tumor necrosis factor. IL-6 triggers hypothalamic arginine vasopressin production with consequent hyponatremia (5, 6 ).

In addition to infections, SIADH may occur in neurological disorders including head injury and stroke, as well as paraneoplastic syndromes and may be associated with the administration of medications such as tricyclic antidepressants and selective serotonin reuptake inhibitors (7, 8, 9) . SIADH should be considered in the differential diagnosis in patients with hyponatremia (serum sodium levels <135 mmol/L) associated with plasma hypo-osmolality, urine hyperosmolality (>100 mosmol/kg), and high urinary sodium (>40 mEq/L). Notably, the serum potassium level is normal, no acid-base disturbance is observed, and the serum uric acid level is frequently low in patients with SIADH (4, 8) .

A systematic review and meta-analysis reported that SIADH-induced hyponatremia was associated with longer length of intensive care unit (ICU) stay and was shown to be associated with a high mortality rate 6 in patients with COVID-19. The prognostic value of this finding remains unclear and requires further investigation (10) . Few case reports have described COVID-19-associated SIADH and hyponatremia. We present a case of hyponatremia secondary to SIADH in a patient with COVID-19 pneumonia and a history of kidney transplantation.

A 76-year-old man with a medical history of living-related kidney transplantation in 2011, type 2 diabetes mellitus, and hypertension presented to the emergency department with nonspecific symptoms, including malaise, headache, poor oral intake, and fatigue. He denied a history of fever, confusion, seizures, chest, or gastrointestinal symptoms and denied the administration of any new medications or changes to his usual prescription. He had recently received the first dose of the COVID-19 vaccine. Current medications included prednisone, tacrolimus, mycophenolate mofetil, nifedipine, losartan, metoprolol, atorvastatin, glipizide, Januvia/Metformin, magnesium oxide, and omeprazole.

Physical examination showed normal vital signs, and volume status evaluation showed euvolemia.

Systemic evaluation including chest and neurological examination was unremarkable.

Urinalysis and brain computed tomography were unremarkable. The patient was admitted to the hospital for appropriate hydration, with a tentative diagnosis of mildly symptomatic hyponatremia secondary to poor oral intake. We initiated intravenous fluid (IVF) administration, and a Foley catheter was inserted to monitor fluid status. Blood work obtained 6 hours later showed worsening hyponatremia with a serum sodium level of 120 mEq/L but normal renal function; therefore, the patient underwent workup for hyponatremia.

The patient's condition worsened 24 hours later, with progressive shortness of breath and low-grade fever but normal blood pressure. Arterial blood gas evaluation results were consistent with severe hypoxemia (type 1 respiratory failure) with anion gap metabolic acidosis. Chest radiography revealed bilateral diffuse interstitial infiltrates (Figure 1 ). We performed reverse transcriptase-polymerase chain reaction (RT-PCR) testing for COVID-19, and the patient was transferred to the ICU for monitoring and respiratory support after discontinuation of IVF. The patient was tentatively diagnosed with respiratory failure secondary to COVID-19 pneumonia. Hyponatremia was likely secondary to SIADH in the setting of chest infection, which was supported by the laboratory test results. Despite trials of continuous positive airway pressure, the patient's respiratory status continued to deteriorate, which eventually necessitated intubation. The patient also received full empirical therapy for suspected COVID-19 pneumonia, including dexamethasone, favipiravir, tocilizumab, and nebulizers, secondary bacterial infection prophylaxis, and modifications to his anti-rejection medications. He remained hemodynamically stable and did not require inotropic or vasopressor support. The patient's COVID-19 test showed positive results, 12 hours later.

The patient's respiratory status slightly improved the following day, and ventilator settings were adjusted to wean the patient from mechanical ventilatory support . He remained intubated in the ICU for 5 days.

His condition gradually improved, and he was successfully extubated and transferred to the general ward following stabilization of his general condition. The patient's renal function remained normal throughout admission, and serum sodium level improved gradually with a parallel improvement in his respiratory status (Table 3) .

Several studies have reported pneumonia associated with SIADH (11, 12, 13) ; however, few case reports have discussed SIADH secondary to COVID-19 pneumonia (14,15). To our knowledge, this is the first case report that describes SIADH-induced hyponatremia in a patient with SARS-CoV-2 infection and a history of kidney transplantation.

Our patient was an elderly man with a history of long-standing diabetes and hypertension and kidney transplantation, who received potent immunosuppressant agents including mycophenolate mofetil. Therefore, the patient was not administered the complete COVID-19 vaccine course.

Immunocompromised patients are known to show greater susceptibility to COVID-19 breakthrough infection (16, 17) . Interestingly, the highest risk was observed among recipients of solid organ transplantation (16 ,17 ,18) .

Furthermore, immunocompromised patients tend to present with atypical clinical manifestations, as observed in the present case (17, 19) . Diagnosis of COVID-19 infection was confirmed using RT-PCR testing, and pneumonia was confirmed based on chest radiography findings, which revealed diffuse bilateral pulmonary infiltrates in our patient. SIADH should be suspected in patients with hyponatremia (serum sodium levels <135 mmol/L), and low plasma osmolality (<280 mosmol/kg), high urine osmolality (>100 mosmol/kg), and high urinary sodium levels (>20 mmol/L) are useful for diagnostic confirmation (3, 20) .

In the present case, laboratory test results revealed severe hyponatremia (serum sodium 120 mmol/L), serum osmolality 230 mosmol/kg, urine osmolality 590 mosmol/kg, high urinary sodium levels (67 mmol/L), and low serum uric acid levels, all of which were consistent with diagnosis of SIADH (3, 4) .

COVID-19-induced hyponatremia is attributed to sepsis and cytokine storm (excessive IL-6 release), which consequently activates the hypothalamic-pituitary-adrenal axis and upregulates arginine vasopressin expression (5,6).

A variety of medications can cause SIADH-induced hyponatremia (7),(8), (9) . However, no medication administered by our patient is reported to cause hyponatremia or SIADH.

Severe hyponatremia can precipitate a variety of neurological symptoms, including lethargy, drowsiness, seizures, and loss of consciousness (19, 22) and may even result in brain stem herniation secondary to cerebral edema. Moreover, rapid correction of hyponatremia can lead to serious neurological insult such as the osmotic demyelination syndrome (23). Fortunately, supportive management in the ICU and optimal treatment of the primary injury (pneumonia) led to gradual improvement in our patient's condition, and his serum sodium levels returned to the normal range.

Hyponatremia observed in recipients of kidney transplants may be multifactorial in origin (24, 25) .

Patients who undergo solid organ transplantation show greater susceptibility to infections and may be predisposed to SIADH-induced hyponatremia. Poor oral intake may contribute to hyponatremia in these patients and may lead to hypovolemic hypo-osmolar hyponatremia (16, 17, 18) . This condition is often therapeutically challenging. IVF administration can worsen hyponatremia in patients with SIADH owing to the desalination phenomenon (26, 27) , although IVF is known to improve serum sodium levels in patients with hypovolemia. IVF administration initially led to worsening of serum sodium levels in our patient; however, these improved gradually parallel with improvement in the patient's respiratory status, all of which support the diagnosis of SIADH-induced hyponatremia in this case.

COVID-19 is associated with the development of SIADH; therefore, this condition should be considered in the differential diagnosis in patients with hyponatremia. Administration of IVF warrants cautious decision-making in these settings to avoid worsening of hyponatremia. Moreover, vaccination of immunocompromised patients (such as those with a history of kidney transplantation) plays a key role in reducing the transmission of the virus and controlling the COVID-19 pandemic.

Patient gave the agreement to publish his case 

Clinical manifestations of COVID-19 in the general population: systematic review

The syndrome of inappropriate antidiuretic hormone secretion

The Clinical Physiology of Water Metabolism: Part III: The Water Depletion (Hyperosmolar) and Water Excess (Hyposmolar) Syndromes. Western Journal of Medicine

Cytokine Storm and its Implication in Coronavirus disease 2019 (COVID-19)

How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms -ScienceDirect

The syndrome of inappropriate antidiuretic hormone secretion: Distribution and characterization according to etiologies

Syndrome of Inappropriate Antidiuretic Hormone Secretion Associated with Head and Neck Cancers: Review of the Literature

Drug-Induced Syndrome of Inappropriate Antidiuretic Hormone Secretion

Frontiers | The Prognostic Value of Hyponatremia for Predicting Poor Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis | Medicine

The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences

Syndrome of Inappropriate Antidiuretic Hormone in a Bulldog with Aspiration Pneumonia

Hyponatraemia and the inappropriate ADH syndrome in pneumonia

A case of Inappropriate Antidiuretic Hormone Secretion Syndrome Associated with COVID-19 Pneumonia

15. syndrome of inappropriate antidiuresis in COVID-19 pneumonia: report of two cases

COVID-19 and comorbidities: Deleterious impact on infected patients

COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve -Fishman -2020 -American Journal of Transplantation -Wiley Online Library

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic

Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH)

Acute symptomatic hyponatremia in setting of SIADH as an isolated presentation of COVID-19 -ScienceDirect

The Prognostic Value of Hyponatremia for Predicting Poor Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Medicine

Effects of Hyponatremia on the Brain

Posttransplant Hyponatremia Predicts Graft Failure and Mortality in Kidney Transplantation Recipients: A Multicenter Cohort Study in Korea

Approach and Management of Hypertension After Kidney Transplantation. Front Med (Lausanne)

Hyponatremia: A practical approach

Understanding and managing hyponatraemia. Paediatrics and Child Health